Chronic Lymphocytic Leukemia: Clinical Trials

7 terminated. 7 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	7	Terminated 7
Phase 2	1	Terminated 1

Follow Chronic Lymphocytic Leukemia: new trials by email Literature Review of Chronic Lymphocytic Leukemia trials Research Report on Chronic Lymphocytic Leukemia

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) Ublituximab, Umbralisib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 2 / Phase 3	Terminated	TG Therapeutics, Inc.	277	2019-05-16	2024-04-19
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia Obinutuzumab, Ublituximab, TGR-1202 - Chronic Lymphocytic Leukemia	Phase 3	Terminated	TG Therapeutics, Inc.	603	2015-11-19	2024-12-13
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia Idelalisib, Chlorambucil, Obinutuzumab - Chronic Lymphocytic Leukemia	Phase 3	Terminated	Gilead Sciences	57	2015-04-21	2018-11-19
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Idelalisib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia	Phase 3	Terminated	Gilead Sciences	311	2014-02-05	2018-11-19
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia Idelalisib, Ofatumumab - Chronic Lymphocytic Leukemia	Phase 3	Terminated	Gilead Sciences	261	2012-12-04	2019-08-14
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) Idelalisib - Chronic Lymphocytic Leukemia	Phase 3	Terminated	Gilead Sciences	161	2012-10-03	2019-08-20
Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Filgrastim, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia	Phase 3	Terminated	German CLL Study Group	83	1999-07-01	2016-09-26

Narrower conditions

Leukemia, Lymphocytic, Chronic, B-Cell (7)  ·  Leukemia (1)

Broader conditions

Chronic Disease (7)  ·  Disease Attributes (7)  ·  Hematologic Diseases (7)  ·  Hemic and Lymphatic Diseases (7)  ·  Immune System Diseases (7)  ·  Immunoproliferative Disorders (7)  ·  Leukemia, B-Cell (7)  ·  Leukemia, Lymphoid (7)  ·  Lymphatic Diseases (7)  ·  Lymphoproliferative Disorders (7)  ·  Neoplasms (7)  ·  Neoplasms by Histologic Type (7)  ·  Pathologic Processes (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Leukemia (6)

Interventions

idelalisib (4)  ·  Chlorambucil (2)  ·  obinutuzumab (2)  ·  ublituximab (2)  ·  umbralisib (2)  ·  Bendamustine Hydrochloride (1)  ·  Cyclophosphamide (1)  ·  Filgrastim (1)  ·  Mitoxantrone (1)  ·  Rituximab (1)  ·  fludarabine (1)  ·  ofatumumab (1)  ·  venetoclax (1)

Sponsors

Gilead Sciences (4)  ·  TG Therapeutics, Inc. (2)  ·  German CLL Study Group (1)

Countries

United States (6)  ·  United Kingdom (5)  ·  France (4)  ·  Poland (4)  ·  Spain (4)  ·  Australia (3)  ·  Belgium (3)  ·  Canada (3)  ·  Italy (3)  ·  Croatia (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Germany (1)  ·  Hungary (1)  ·  Ireland (1)

Top investigators

Michael Hallek, MD (1)

Results publications

PMID 28257752, PMID 30995176, PMID 32599655

NIH funding

2015 (1)